Don Huffman (independent, audit committee) A senior financial and corporate development executive, Don Huffman has raised $700 million in equity and debt financing and assisted in structuring $650 million in merger, acquisition, and spinout transactions. Huffman has held the office of CFO at three companies with active programs in Diabetes: EndoSonics Corporation, a NASDAQ-listed manufacturer of medical devices (now the +$1 billion Volcano Corporation); Microcide Pharmaceuticals; and Celtrix Pharmaceuticals, where he assisted in successful merger outcomes for these NASDAQ-listed companies. Huffman also served as CFO and Principal of Sanderling Ventures, a $1.2 billion toptier biomedical venture capital firm, and participated in raising a $420 million fund. Huffman received his B.S. from Pennsylvania State University and an M.B.A. from the State University of New York at Buffalo. He completed the Financial Management Program at the Stanford University Graduate School of Business. He qualifies as an “audit committee financial expert” per SEC and SOX requirements.
News 
Market Data 
Discover 
